Clinical trial
Modified-release Dipyridamole/Aspirin (200mg/25mg bd) Versus Aspirin (75mg) in…
NCT00129038 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00129038 |
|---|---|
| Title | Modified-release Dipyridamole/Aspirin (200mg/25mg bd) Versus Aspirin (75mg) in Aspirin-resistant Patients |
| Official title | A Randomised, Crossover Study Comparing the Biochemical and Platelet Effects of Modified-release Dipyridamole/Aspirin (200mg/25 mg bd; Asasantin Retard®) With Aspirin (75 mg qd) in Coronary Artery Disease Patients With Aspirin Resistance Manifesting as Persistent Thromboxane Formation. |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Coronary Arteriosclerosis |
| Intervention type | Drug |
| Interventions | modified-release dipyridamole/aspirin, aspirin |
| Enrollment | 11 |
| Start date | Apr 1, 2004 |
| Primary completion | Jan 1, 2007 |
| First posted | Aug 11, 2005 |
| Last update posted | Jan 23, 2025 |
| Countries | Ireland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: